- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06581549
Profilage du microenvironnement immunitaire et de l'expression génique dans le mésothéliome (Imaging-Meso)
De la caractérisation du microenvironnement immunitaire et du profilage de l'expression génique aux tests de nouveaux médicaments dans le mésothéliome pleural et péritonéal : étude d'imagerie-méso
Pleural and peritoneal mesotheliomas (PPM) are rare cancers mostly related to asbestos-exposure, which are characterized by a complex histopathological diagnosis and staging, few therapeutic options and a dismal prognosis. The main unmet medical need in PPM is the lack of a treatment sequence for affected patients. The advent of immune checkpoint inhibitors has changed the first line treatment of PPM, thanks to the improvement in survival achieved by the combination of ipilimumab and nivolumab that are currently approved for non-epithelioid histology in our Country.
PPM is characterized by a large heterogeneity of the genomic landscape, which is mainly characterized by the loss of tumour suppressor genes and mutations in DNA repair genes and by an "altered- suppressed" or "excluded" tumor immune microenvironment (TIME).
The goal of this project is to improve the immune-biological and molecular stratification of PPM subgroups that can lead to the identification of different personalized treatment approaches. PPM patients (N=220) will be retrospectively (N=150) and prospectively (N=70) recruited from the coordinator center and 6 participating Italian centers. Treatment-naïve tumor samples will be collected and analyzed by bulk gene expression and spatial whole transcriptome analysis, and by 9-color multiplex immunofluorescence.
New targets or actionable pathways potentially emerging from such studies will be finally assessed and validated in patient-derived organoids/xenografts that accurately reflect PPM tumorigenesis.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Alessandria, Italie, 15121
- Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo
-
Bergamo, Italie
- Asst Papa Giovanni Xxiii Bergamo
-
Genova, Italie
- Ircss Ospedale Policlinico San Martino
-
Milan, Italie
- Asst Grande Ospedale Metropolitano Niguarda-Milano
-
Milan, Italie
- Fondazione Ircss Istituto Nazionale Dei Tumori Di Milano
-
Padova, Italie, 35128
- Istituto Oncologico Veneto
-
Parma, Italie, 43126
- Azienda Ospedaliera-Universitaria di Parma
-
Verona, Italie
- Azienda Ospedaliera Universitaria Integrata Verona
-
-
Milano
-
Rozzano, Milano, Italie, 20089
- Istituto Clinico Humanitas
-
-
Pordenone
-
Aviano, Pordenone, Italie, 33081
- Centro di Riferimento Oncologico (CRO) IRCCS
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
220 PPM patients will be enrolled in 7 Centers, 150 retrospectively and 70 prospectively.
La description
Inclusion Criteria:
- Patients with Mesothelioma of the Pleura and Peritoneum
- Age greater than 18 years of age
- Patients undergoing surgery will require both biopsy and surgical sampling material
- Pathologist's confirmation of the presence of tumor sections in the excised specimens
- Patients in follow-up from active cancer treatment for at least 6 months
Exclusion Criteria:
- Inadequacy of biological material for analysis under study
- Patients not amenable to active oncologic treatment
- Patients lost to follow-up before 6 months after the end of active oncologic treatment
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: OTHER
- Perspectives temporelles: OTHER
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Primary outcome
Délai: Through study completion, an average of 3 years
|
PPM treatment-naïve tumor samples and classification in different clusters according to the differential expression of molecular and gene signatures by Gene expression profile (GEP) analysis. |
Through study completion, an average of 3 years
|
|
Primary outcome
Délai: Through study completion, an average of 3 years
|
Identification of molecular and immune signatures predictive of resistance or sensitivity to systemic anticancer drugs: chemotherapy or immunotherapy administered as first line treatment by spatial whole transcriptome analysis. |
Through study completion, an average of 3 years
|
|
Primary outcome
Délai: Through study completion, an average of 3 years
|
PPM surgical specimens and comparison with GEP in matched treatment-naïve tumor samples will be performed by gene expression profile analysis with GEP analysis. |
Through study completion, an average of 3 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Secondary outcome
Délai: Through study completion, an average of 3 years
|
Characterization and quantification of immune cell distribution and their spatial relationships in treatment naïve tumor samples of PPM patients will be performed by a 9-color multiplex immunofluorescence (mIF) analysis. |
Through study completion, an average of 3 years
|
|
Secondary outcome
Délai: Through study completion, an average of 3 years
|
Immune phenotypes defined by mIF and the immune signatures identified by GEP analyses will be performed in each treatment-naïve tumor sample. |
Through study completion, an average of 3 years
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Third outcome
Délai: Through study completion, an average of 3 years
|
In vitro and in vivo models of PPM for the investigation of activated signatures, new therapeutic targets and drug sensitivity tests. will be performed by:
|
Through study completion, an average of 3 years
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Giulia Pasello, MD, Istituto Oncologico Veneto IOV IRCCS
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- Imaging-Meso study
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .